Sanofi halts development of Kymab-derived OX40L antibody for atopic dermatitis

Sanofi announced that it will no longer pursue the OX40L antibody program it was developing with Kymab for the treatment of atopic dermatitis. The drug was being positioned as a potential follow‑on to the company’s blockbuster eczema therapy Dupixent.

The decision reflects Sanofi’s assessment that the candidate will not meet its expectations for efficacy or commercial potential. As a result, the company will cease further clinical work and will not file for regulatory approval.

The move removes a prospective addition to Sanofi’s dermatology pipeline, but the firm continues to focus on its existing portfolio and other pipeline assets.